Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma …

on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group

Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR, Berthold F.

Cancer. 2017 Apr 1;123(7):1095-1105. doi: 10.1002/cncr.30380. Epub 2016 Dec 16. PMID: 27984660.

Previous
Previous

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as HD chemotherapy for HR neuroblastoma (HR-NBL1 ph3 trial /SIOPEN)

Next
Next

(123)I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting, method by an international panel